Immunome, Inc. (IMNM) vs Novavax, Inc. (NVAX)
- Immunome, Inc. IMNM 16.47 −5.34%
- Novavax, Inc. NVAX 11.26 −12.17%
Immunome, Inc. and Novavax, Inc. are both Biotechnology companies. Immunome, Inc. and Novavax, Inc. are of similar size ($2.1B and $2.1B). Immunome, Inc. grew revenue faster over the last twelve months: 16.7% against −61.6%. Immunome, Inc. has the higher net margin (0.00% vs −59.9%) and the lower return on invested capital (−3,323.0% vs 0.00%). Across the 16 metrics below, Novavax, Inc. leads on 10 and Immunome, Inc. on 6.
Valuation
Profitability
| Metric | IMNM | NVAX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 78.60% | 65.16% |
| Operating margin | 0.00% | (56.58%) | 0.00% |
| Net margin | 0.00% | (59.87%) | 0.00% |
| Free cash flow margin | 0.00% | (10.20%) | 0.00% |
| Return on equity | (64.03%) | 323.66% | (56.36%) |
| Return on assets | (59.03%) | (21.62%) | (48.04%) |
| Return on invested capital | (3,322.99%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack